Opinion/decision on a Paediatric investigation plan (PIP): Doptelet,Avatrombopag, decision type: , therapeutic area: , PIP number: P/0482/2020

Opinion/decision on a Paediatric investigation plan (PIP): (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4- fluoropyrrolidine-2-carboxamide (ACH-0144471), decision type: , therapeutic area: , PIP number: P/0243/2019

Human medicines European public assessment report (EPAR): Revolade, eltrombopag, Purpura, Thrombocytopenic, Idiopathic, Date of authorisation: 11/03/2010, Revision: 34, Status: Authorised

5 fluorouracil (topical application) : List of nationally authorised medicinal products - PSUSA/00010000/202301

PRAC recommends new measures to avoid topiramate exposure in pregnancy

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 August 2023

Tetanus vaccines : List of nationally authorised medicinal products - PSUSA/00002910/202301

Cefprozil : List of nationally authorised medicinal products - PSUSA/00000605/202212

Human medicines European public assessment report (EPAR): Tafinlar, dabrafenib, Melanoma, Date of authorisation: 26/08/2013, Revision: 29, Status: Authorised

Allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis L.(sublingual tablet) : List of nationally authorised medicinal products - PSUSA/00010465/202212